DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

480 Twyman RE, Rogers CJ, Macdonald RL. Differential regulation
of -aminobutyric acid receptor channels by diazepam and phenobarbital.
Ann Neurol, 1989, 25:213–220.
Uhlenhuth EH, Balter MB, Ban TA, Yang K. International study
of expert judgment on therapeutic use of benzodiazepines and
other psychotherapeutic medications: IV. Therapeutic dose
dependence and abuse liability of benzodiazepines in the longterm
treatment of anxiety disorders. J Clin Psychopharmacol,
1999, 19(Suppl 2):23S–29S.
Victorri-Vigneau C, Dailly E, Veyrac G, Jolliet P. Evidence of
zolpidem abuse and dependence: results of the French Center
for Evaluation and Information on Pharmacodependence
(CEIP) network survey. Br J Clin Pharmacol, 2007,
64:198–209.
Walsh JK, Vogel GW, Schart M, et al. A five-week polysomnographic
assessment of zaleplon 10 mg for the treatment of primary
insomnia. Sleep Med, 2000, 1:41–49.
SECTION II
Whiting PJ. The GABA A
receptor gene family: New opportunities
for drug development. Curr Opin Drug Discov Dev, 2003,
6:648–657.
Woods JH, Katz JL, Winger G. Benzodiazepines: Use, abuse,
and consequences. Pharmacol Rev, 1992, 44:151–347.
Woods JH, Winger G. Abuse liability of flunitrazepam. J Clin
Psychopharmacol, 1997, 17:1S–57S.
Zammit G. Comparative tolerability of newer agents for insomnia.
Drug Safety, 2009, 32:735–748.
Zammit G, Erman M, Wang-Weigand S, et al. Evaluation of the
efficacy and safety of ramelteon in subjects with chronic
insomnia. J Clin Sleep Med, 2007, 3:495–504.
NEUROPHARMACOLOGY